Browsing Tag
TSC-101
2 posts
TScan launches Phase 3 ALLOHA-2 with $128m in cash and a looming funding gap
TSC-101 enters Phase 3 as TScan weighs promising donor-chimerism data against manufacturing complexity and a pre-readout funding gap.
Does FDA clearance across three HLA subtypes de-risk TScan Therapeutics’ platform strategy?
FDA clears TSC-102-A01 and TSC-102-A03 for TScan Therapeutics. Explore how expanded HLA reach reshapes its heme cell therapy strategy.